New hope for tough stomach cancers: Final-Stage trial tests targeted drug
NCT ID NCT06351020
Summary
This study is testing an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). It is for patients whose cancer has continued to grow after trying at least two other treatments. The main goals are to see if LM-302 helps people live longer and keeps the cancer from growing compared to other available options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC GC AND GCJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.